Coherus Oncology, Inc. (CHRS) Balance Sheet
As of 2026-06-30 (10-Q), Coherus Oncology, Inc. (CHRS) reported total assets of $191.2M, total liabilities of $130.3M and shareholders' equity of $60.8M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $82.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CHRSCoherus Oncology, Inc.Follow CHRS — free
—
Price chart with a free account
- Market cap
- 156.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 150.4 | 158.2 | 124.9 | 126.9 | 72.4 | 177.7 | 541.2 | 417.2 | 63.5 | 102.9 | 126.0 | 88.9 | 82.9 | |
| Short-term investments | — | — | — | — | 0.0 | 0.0 | — | — | 128.1 | 14.9 | — | 83.2 | 22.4 | |
| Receivables | 2.4 | 1.6 | 1.9 | — | 0.0 | 142.0 | 157.0 | 123.0 | 110.0 | 260.5 | 111.3 | 17.8 | 13.9 | |
| Inventory | — | — | — | — | 1.7 | 9.8 | 44.2 | 37.6 | 38.8 | 62.6 | 4.2 | 3.2 | 5.7 | |
| Current assets | 179.1 | 197.4 | 161.5 | 145.5 | 84.4 | 343.0 | 767.5 | 602.3 | 381.2 | 475.6 | 341.6 | 206.7 | 133.8 | |
| Total assets | 187.2 | 212.4 | 178.5 | 162.6 | 99.5 | 408.9 | 841.6 | 679.3 | 480.8 | 629.6 | 448.5 | 258.3 | 191.2 | |
| Current liabilities | 51.8 | 106.0 | 56.4 | 28.4 | 33.3 | 115.0 | 145.7 | 165.3 | 138.7 | 331.8 | 283.0 | 140.4 | 75.5 | |
| Long-term debt | — | — | — | — | 0.0 | 73.7 | — | — | — | — | — | — | — | |
| Total liabilities | 120.5 | 219.3 | 159.1 | 132.1 | 138.1 | 303.7 | 560.7 | 581.6 | 618.3 | 823.0 | 580.5 | 197.3 | 130.3 | |
| Shareholders' equity | 66.8 | -6.2 | 20.5 | 30.5 | -38.6 | 105.2 | 281.0 | 97.7 | -137.4 | -193.4 | -132.0 | 61.0 | 60.8 |
USD millions · SEC XBRL
Coherus Oncology, Inc. — questions
- How much cash does Coherus Oncology, Inc. have?
- $82.9M in cash and cash equivalents as of 2026-06-30.
- What are Coherus Oncology, Inc.'s total assets?
- $191.2M as of 2026-06-30.
- What is Coherus Oncology, Inc.'s shareholders' equity?
- $60.8M as of 2026-06-30.
Every figure on this page comes from Coherus Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.